Introdução: O gênero Acinetobacter representa um importante patógeno relacionado a infecções hospitalares, principalmente, à pneumonia associada à ventilação mecânica (PAV). O aumento de isolados de Acinetobacter baumannii resistentes aos carbapenêmicos (ABRC) representa um problema mundial, pois limita drasticamente as opções terapêuticas. A produção da carbapenamase OXA-23, uma β-lactamase da classe D de Ambler, representa o principal mecanismo responsável por esta resistência em nosso país. Objetivo: O presente estudo tem como objetivo padronizar a técnica de PCR em tempo real (qPCR) para a detecção do gene blaOXA-23 diretamente de aspirados traqueais (ATs) de pacientes com suspeita de pneumonia associada à ventilação mecânica (PAV) de unidades de tratamento intensivo (UTIs). Métodos e resultados: O DNA das amostras de ATs coletadas de pacientes em ventilação mecânica foi analisado pela técnica de qPCR, utilizando o SYBR green, para a detecção do gene blaOXA-23. Dentre os 20 ATs analisados, ABRC foi isolado em 10, A. baumannii sensível aos carbapemêmicos (ABSC) em 3 e 7 foram negativos na culura bacteriológica. O gene blaOXA-23 foi detectado tanto na colônia quanto no AT em 8 das 10 amostras de ABRC. Em uma amostra não houve detecção do gene por qPCR em nenhum dos materiais e em outra amostra houve detecção só no AT. Dos ABSC, em duas amostras não houve detecção do gene na colônia e no AT enquanto que em uma amostra o gene foi detectado somente no AT. Em nenhuma das amostras de ATs negativas na cultura foi detectado o gene. Conclusão: O estudo sugere que a técnica qPCR pode ser aplicada para a detecção do gene blaoxa-23 diretamente de amostras de AT, reduzindo assim, o tempo para o início de uma terpia antimicrobiana adequada e melhorando, consequentemente, o desfecho clínico deste pacientes. / Background: The genus Acinetobacter is an important pathogen associated with nosocomial infections mainly ventilator-associated pneumonia (VAP). The increasing of carbapenemresistant Acinetobacter baumannii (CRAB) isolates is a worldwide concern since it limits drastically the range of therapeutic alternatives. The OXA-23 producing, a carbapenemhydrolysing class D β-lactamase, is the major mechanism responsible for CRAB in our country. Objective: The study objective is to develop a real time PCR (qPCR) to detect the Acinetobacter baumannii blaOXA-23 gene directly in endotracheal aspirate (ETA) of patients under mechanical ventilation, with suspected ventilator-associated pneumonia (VAP). Methods and Results: DNA extracted from ETA samples from patients under mechanical ventilation was analyzed by qPCR, using SYBR green, for the presence of blaOXA-23 gene. Among the 20 ETAs examined, CRAB isolates were recovered in 10 quantitative cultures; carbapenem-susceptible A. baumannii (CSAB) in 3 and 7 cultures were negative to A. baumanni. Of the 10 CRAB, 8 were positive for blaOXA-23 on both the colony and ETA. In one blaOXA-23 qPCR was negative in colony and directly from ETA, while the other showed a qPCR negative result in the colony and positive in the ETA. In 3 CSAB, 2 samples showed negative results in colony and ETA and one showed a blaOXA-23 positive result only from the ETA. None of the 7 negative ETAs were positive for blaOXA-23 gene in the qPCR of the ETA. Conclusion: Our study suggests that qPCR can be applied to detect the presence of blaOXA-23 gene directly from ETAs reducing the time to an earlier initiation of appropriate therapy improving, consequently, the clinical outcomes for these patients.

The genus Acinetobacter currently contains 34 species, the vast majority of which are not regularly implicated in causing infection. However, incidences of hospitalacquired infection with Acinetobacter species are increasing, mainly due to the rise in the number of infections caused by the species Acinetobacter baumannii in immunocompromised patients particularly in intensive care units (ICUs). Due to high levels of resistance in A. baumannii to many classes of antibiotic, the carbapenems have been portrayed as the ‘drugs of choice’ for treating infections with this species. However, the activity of the carbapenems against A. baumannii has come under threat with the identification of four groups of class D β-lactamases carried by members of the species. Of these, the OXA-51-like enzymes have been suggested to be ubiquitous and intrinsic enzymes within A. baumannii. This presents the worrying scenario of the potential for all A. baumannii to become carbapenem resistant, leaving few treatment options available for this species. This project aimed to investigate the epidemiological spread of the OXA-51-like β-lactamases, examine the diversity within these enzymes, and whether this diversity may have implications for their ability to confer resistance to the carbapenems. A functional map showing the amino-acid similarities between the OXA-51-like enzymes demonstrated that the enzymes fall into distinct closely-related groups, with notable clusters surrounding OXA-66, OXA-69 and OXA-98. PCR and sequencing analysis of a geographically diverse group of 64 A. baumannii isolates demonstrated that isolates forming specific sequence groups (SGs) as defined by Turton et al (2007) also contained the same or closely related blaOXA-51-like gene. Higher minimum inhibitory concentrations (MICs) of carbapenems were found in association with acquired carbapenemases, or with the presence of ISAba1 upstream of the blaOXA-51- like gene. Pulsed-field gel electrophoresis (PFGE) analysis of the isolates did not demonstrate relatedness between isolates which formed the same sequence group. Multilocus sequence typing (MLST) of a subset of 44 isolates grouped isolates more consistently with the SGs and blaOXA-51-like alleles, indicating that PFGE is unreliable for use with A. baumannii unless studying a short time period, and that blaOXA-51-like alleles are a good epidemiological marker. Mutation studies using meropenem with five A. baumannii isolates encoding different OXA-51-like enzymes, while resulting in an increase in meropenem MICs of between 8- and 128-fold, did not result in a nucleotide substitution in the blaOXA- 51-like genes or a change in the upstream region of the genes in any isolate suggesting that the carbapenems may not be producing a strong selective pressure on the blaOXA- 51-like genes. Analysis of πN/πS ratios for the blaOXA-51-like genes, MLST genes and the TEM, SHV and CTX-M β-lactamase families showed the blaOXA-51-like genes to be under less positive selection than these other β-lactamases, though under less purifying selection than the MLST genes. Phylogenetic analysis of the MLST genes and the blaOXA-51-like genes indicates that the blaOXA-51-like genes have been evolving within A. baumannii since its speciation, and that different groups of blaOXA-51-like genes have been evolving at different rates corresponding to different rates of evolution within their parent lineages. Structural modelling studies based upon the published crystal structure for OXA-40 indicated that amino-acid variation at particular sites in the OXA-51-like enzymes are likely to have an effect of enzyme function. Alterations at amino-acid position 167 change the shape of the entrance to the active site which may affect hydrolysis by accommodating the antibiotic differently, or may affect the substrate profile of the enzyme. The substitution of glutamine for proline at position 194 may significantly alter the shape of the enzyme thereby affecting substrate hydrolysis. This project found that specific groups of blaOXA-51-like genes are associated with specific A. baumannii lineages and that these genes could serve as convenient epidemiological markers. Most of the diversity within the OXA-51-like enzymes is due to their continued evolution within A. baumannii since the species’ emergence. However, certain amino-acid changes may play a role in altering the rate of hydrolysis or substrate profile of these enzymes.

Acinetobacter baumannii es un cocobacilo aeróbico, Gram negativo y considerado un patógeno nosocomial emergente, que ha desarrollado resistencia a múltiples fármacos. El presente trabajo tuvo como objetivo determinar la resistencia antimicrobiana de cepas de Acinetobacter baumannii aisladas de pacientes internados en el Hospital Nacional Guillermo Almenara Irigoyen y relacionarlo con la presencia de plásmidos, así como determinar la prevalencia de esta especie en dicho nosocomio según el servicio de hospitalización, tipo de muestra, edad, sexo y factores de comorbilidad, mortalidad y estacionalidad. Se identificaron 40 cepas de A. baumannii de origen clínico aisladas de muestras de pacientes hospitalizados del nosocomio Guillermo Almenara Irigoyen durante enero-diciembre del 2012. Las cepas fueron identificadas mediante el sistema automatizado Micro Scan y el método convencional. Se utilizo Agar MacConkey y Agar Leeds Acinetobacter, incubándose a 37 y 44°C respectivamente, en la coloración Gram se observaron cocobacilos Gram negativas, se hicieron pruebas bioquímicas como TSI, citrato y gelatina además de la pruebas de oxidasa y catalasa. Se realizó la sensibilidad antimicrobiana a través del sistema automatizado Micro Scan y el método de difusión en disco. El 100% de las cepas mostraron resistencia a cefalosporina de tercera generación, meropenem, imipenem, ciprofloxacino, ticar/Ac. clavulánico. El 93.5% fueron resistentes a cefepime y sulfametoxazol-trimetoprim, el 95 % a levofloxacino, el 90% a amikacina, el 45% a gentamicina, el 37.5% a tobramicina y el 30% a tetraciclina. Se registraron 12 antibiotipos de resistencia, con una mayor frecuencia en el servicio de Unidad de cuidados Intensivos. Se determinó el perfil plasmídico de las cepas estudiadas, obteniendo 31 perfiles según el número y tamaño de las bandas, que oscila entre 1,240 - 55,459 pb aproximadamente; luego se relacionó con los patrones de resistencia y el origen de aislamiento de la cepa. Además se realizó la curación de las cepas con bromuro de etidio a una concentración del 300 µg/ml. Las cepas que perdieron la resistencia fueron interpretadas como portadoras de resistencia plasmídica a los determinados antibióticos. Además se determinó una prevalencia del 7.42% de total de bacterias gram negativas aisladas, presentando un mayor número de casos en los meses de verano e invierno, con una misma proporción para ambos sexos, la edad promedio de los pacientes infectados fue 62.314±19.745. A.baumannii se aisló principalmente de muestras respiratorias, seguida de hemocultivos y líquidos biológicos provenientes del servicio de UCI, Medicina Interna 1 y Cirugía General 5. Las infecciones se asociaron a pacientes con estados de inmunosupresión debido a procesos quirúrgicos y enfermedades base como cáncer, insuficiencia hepática crónica, insuficiencia renal y EPOC. La tasa de mortalidad asociada a la infección fue del 56.4%. / ---- Acinetobacter baumannii is an aerobic, Gram-negative coccobacillus and is considered an emerging nosocomial pathogen that has developed resistance to multiple drugs. The present study aimed to determine the antimicrobial resistance in Acinetobacter baumannii strains isolated from patients hospitalized in the Guillermo Almenara Irigoyen National Hospital and its relationship with the presence of plasmids, and determine the prevalence of this species in that hospital according to the inpatient service , sample type, age, sex and comorbidity, mortality and seasonality factors. 40 A. baumannii strains of clinical origin, isolated from samples of hospitalized patients at the Guillermo Almenara Irigoyen hospital during January and December 2012, were identified. Strains were identified by the MicroScan Automated System and by the conventional method. MacConkey Agar and Leeds Acinetobacter Agar were used, incubating at 37 and 44ºC, respectively. Gram-negative coccobacillus were observed in the Gram stain. Biochemical test including TSI, citrate and gelatin were performed, in addition to the oxidase and catalase tests. Antimicrobial susceptibility testing was performed using the Micro Scan automated system and the disk diffusion method. 100% of the strains showed resistance to third-generation cephalosporin, meropenem, imipenem, ciprofloxacin, ticar / clavulanic acid. 93.5% were resistant to cefepime and trimethoprim-sulfamethoxazole, 95% to levofloxacin, 90% to amikacin, 45% to gentamicin, 37.5% to tobramycin and 30% to tetracycline. 12 resistance antibiotypes were recorded, with more frequency in the intensive care unit service. The plasmid profile of the studied strains was determined, obtaining 31 profiles according to the number and size of the bands, which ranged from about 1,240– 55,459 bp; these were then associated with the resistance patterns and the isolation origin of the strain. Furthermore, strain curing was performed with ethidium bromide at a concentration of 300 µg/ml. Strains that lost resistance were interpreted as strains carrying plasmidic resistance to certain antibiotics. Moreover, a prevalence of 7.42% of total isolated Gram-negative bacteria was determined, presenting a larger number of cases in the summer and winter, with the same proportion for both sexes; the average age of infected patients was 62.314 ± 19.745. A. baumannii was mainly isolated from respiratory samples, followed by blood cultures and biological fluids samples from the UCI service, Internal Medicine 1 and General Surgery 5. The infections were associated to patients with immunosuppression state caused by surgical procedures and underlying diseases such as cancer, chronic liver failure, kidney failure and EPOC. The mortality rate associated with infection was 56.4%. Keywords: Acinetobacter baumannii, nosocomial infection, antimicrobial resistance plasmids, plasmids healing, hospital prevalence.

Orientador: Mara Corrêa Lelles Nogueira / Banca: Alessandra Vidotto / Banca: Fátima Pereira de Souza / Resumo: Acinetobacter baumannii é frequentemente encontrado em infecções hospitalares, ocasionando pneumonia associada à ventilação, bacteremia, infecções de trato urinário e meningite secundária. Nos últimos anos, o uso extensivo de antimicrobianos em hospitais contribuiu para o aumento e emergência de cepas resistentes, incluindo os carbapenêmicos, os principais recomendados no tratamento. Assim, os aminoglicosídeos ganham importância como opção terapêutica. A resistência a estes antimicrobianos é decorrente, principalmente, da produção de enzimas modificadoras de aminoglicosídeos (AMEs) e de enzimas 16S rRNA Metilases. No Brasil, informações sobre o perfil de suscetibilidade e genes que codificam estas enzimas são escassas. Assim, é fundamental a identificação de mecanismos de resistência e reservatórios potenciais, bem como realizar comparação de isolados para controlar a disseminação de A. baumannii no ambiente hospitalar. O presente estudo teve como objetivos avaliar e comparar o perfil de suscetibilidade aos antimicrobianos, genes de enzimas modificadoras de aminoglicosídeos (AMEs), genes de enzimas 16S rRNA Metilases e similaridade genética entre isolados de A. baumannii com importância clínica no Hospital de Base (HB) de São José do Rio Preto, SP. Além disso, estes resultados foram comparados com um estudo anterior realizado no mesmo hospital. Foram avaliados 32 isolados coletados no período entre dezembro de 2013 a maio de 2014. A identificação da espécie foi realizada por metodologias automatizadas e confirmada por Duplex-PCR. Os testes de suscetibilidade aos antimicrobianos foram resultantes de teste automatizado de microdiluição e disco-difusão, para aminoglicosídeos Amicacina (AK), Gentamicina (CN), Tobramicina (TOB) e Canamicina (CAN), de acordo com o CLSI, 2014 e FDA, 2013. Primers específicos e PCRmultiplex foram usados para a detecção dos genes... / Abstract: Acinetobacter baumannii is found in nosocomial infections, causing ventilator-associated pneumonia, bacteremia, urinary tract infections and secondary meningitis. In recent years, the extensive use of antibiotics in hospitals has contributed to the rise and emergence of A. baumannii strains resistant to a wide range of antimicrobials, including carbapenems, main antibiotics recommended on treatment. In this context, aminoglycosides gain importance as therapeutic options. Resistance to aminoglycosides is mainly due to the Aminoglycoside Modifying Enzymes (AMEs) and 16S rRNA Methylases production. In Brazil, high infection rates to carbapenem-resistant A. baumannii are observated, however information about aminoglycoside susceptibility profile and occurance of this genes are scarce. Thus, it is essential to identify resistance mechanisms and potential reservoirs, as well as perform comparison of isolates to control the spread of A. baumannii in the hospital environment. This study aimed to evaluate and compare the antimicrobial susceptibility profile, genes of aminoglycoside modifying enzymes and 16S rRNA Methylases and genetic similarity among A. baumannii isolates with clinical importance at Hospital de Base (HB) in São José do Rio Preto, SP. Additionally, the results were compared to another previous study achieved in the same hospital. 32 isolates collected between December 2013 and May 2014 were evaluated. Specie identification was performed using automated methodology and confirmed by Duplex- PCR. The susceptibility tests were the result of automated and disc-diffusion tests - for aminoglycosides Amikacin (AK), Gentamicin (CN), Tobramycin (TOB) and Kanamycin (K) - according to CLSI, 2014 and FDA, 2013. Specific primers and Multiplex-PCR were used in AMEs' and 16S rRNA Methylases' genes detection and primers REP1-REP2 were used in molecular typing by REP-PCR. All the isolates of this study... / Mestre

Introdução: O Acinetobacter spp. é um cocobacilo gram-negativo de grande importância nas infecções hospitalares, especialmente em pacientes internados em unidades de terapia intensiva (UTI); podendo levar a um aumento na morbidade e mortalidade desses pacientes. Há evidências sustentando associação entre infecção por Acinetobacter baumannii e aumento das taxas de mortalidade bruta e atribuível. Contudo, o papel desse agente como causa direta de mortalidade ainda não está suficientemente caracterizado. Dentre os fatores relacionados com o aumento da mortalidade estão: gravidade do paciente, infecção relacionada à A. baumannii multirresistente, tratamento com antimicrobiano inadequado, tempo de hospitalização com alta permanência, choque séptico e imunossupressão. Objetivos: Estimar a mortalidade bruta e atribuível às infecções hospitalares causadas pelo Acinetobacter baumannii resistente a antimicrobianos carbapenêmicos (CRAB) por meio de revisão sistemática e metanálise de estudos observacionais. Métodos: Foi desenvolvida uma revisão sistemática e metanálise de estudos observacionais publicados nas bases de dados: MEDLINE/Pubmed, CENTRAL/Cochrane Library, EMBASE/Elsevier, SCOPUS/Elsevier, Web of Science/Thomson Reuters e LILACS/BVS, para estimar a mortalidade bruta e atribuível à infecção hospitalar causada pela bactéria A. baumannii resistente a antimicrobianos carbapenêmicos em pacientes adultos e pediátricos internados em unidades de tratamento intensivo e nãointensivo. Os estudos incluídos caracterizaram fatores preditores de mortalidade associada à infecção por CRAB, comparando com pacientes infectados por A. baumannii sensível a carbapenêmicos (CSAB). Primeiramente, foi estimado um modelo de efeitos aleatórios para a medida agregada de mortalidade atribuível não ajustado a fim de avaliar a contribuição direta das infecções na morte. Na sequência, foram avaliados descritivamente os principais aspectos metodológicos necessários aos estudos observacionais, para a análise dos fatores de risco relacionados a mortalidade atribuível em pacientes infectados por CRAB, por meio de instrumento elaborado conforme recomendações internacionais - ORION, TREND, STROBE e CONSORT. Resultados: Com base nos 29 estudos incluídos na metanálise, observou-se um risco atribuível aumentado na mortalidade bruta em pacientes com infecção por CRAB comparativamente aos pacientes com infecção por CSAB (RA = 0,19 (IC95% = 0,14-0,24) com elevada heterogeneidade (I2 = 66,4%, p-valor < 0,001). Como fontes de heterogeneidade investigou-se o tempo de internação, sítio de infecção, gravidade da doença e uso de terapia inapropriada. Entre os estudos que avaliaram exclusivamente pacientes com bacteremia, o risco de mortalidade atribuível foi maior (RA = 0,27; IC95% = 0,19-0,34). Utilizando-se metarregressão foi observada relação linear positiva entre o risco atribuível de mortalidade e a diferença da média padronizada do escore de APACHE II. Para a investigação da presença de risco de viés e confundimento avaliou-se descritivamente os principais aspectos metodológicos necessários aos estudos observacionais que identificam os fatores de risco associados com a mortalidade atribuível em pacientes com infecções por CRAB. Observou-se nesta revisão que os estudos estão sujeitos a confundimento, incluindo a forma inadequada do ajuste para fatores de confusão de variáveis importantes (ex.: seleção de grupo controle, exposição prévia aos antimicrobianos, mensuração do tempo em risco e a gravidade), além da grande heterogeneidade entre os estudos, devido aos desenhos, unidades de análise e abordagens na medida de exposição e desfecho, tornando difícil a comparação e a sumarização das informações. Conclusões: Os dados dessa revisão sistemática fornecem evidências que a mortalidade atribuível relacionada à presença de infecção por CRAB é maior que em pacientes com infecção por CSAB. Contudo, a investigação da mortalidade atribuível apresenta muitas limitações e ainda não é conclusiva em razão da adequação do desenho do estudo aos seus objetivos; definições de medidas de exposição e desfecho; métricas utilizadas na aferição dos resultados; seleção de grupo controle e fatores de confusão. A consciência de todos esses elementos para a interpretação epidemiológica é vital na análise da mortalidade bruta e atribuível. / Introduction: Acinetobacter spp. is a gram-negative coccobacillus of great importance in hospital infections, especially in patients in intensive care units (ICUs); may lead to an increase in morbidity and mortality of these patients. There is evidence supporting association between infection by Acinetobacter baumannii and the increase in crude and attributable mortality rates. However, the role of this agent as a direct cause of death is not sufficiently characterized yet. Among the factors related to the increase of mortality are: severity of the patient, infection related to A. baumannii multidrug-resistant, inappropriate antimicrobial treatment, hospital stay with high permanence, septic shock and immunosuppression. Objectives: To estimate the crude and attributable mortality to hospital-acquired infections caused by carbapenem-resistant Acinetobacter baumannii through systematic review and meta-analysis of observational studies. Methods: A systematic review and metaanalysis of observational studies published in the databases has been developed: MEDLINE/PubMed, CENTRAL/Cochrane Library, EMBASE/Elsevier, SCOPUS/Elsevier, Web of Science/Thomson Reuters and LILACS/BVS to estimate the crude and attributable mortality to hospital infection caused by the bacterium carbapenem-resistant A. baumannii (CRAB) in adult and pediatric patients in intensive and non-intensive care units. The studies included characterized predictors of mortality associated to infection with CRAB, compared to patients infected with carbapenem-susceptible A. baumannii (CSAB). First, a random effects model was estimated for the aggregate measure of non-adjusted attributable mortality in order to assess the direct contribution of infections in death. Following were descriptively assessed the main methodological aspects necessary to observational studies for the evaluation of risk factors related to attributable mortality in patients infected with carbapenem-resistant A. baumannii through instrument designed according to international recommendations - ORION, TREND, STROBE and CONSORT. Results: Through the 29 studies included in the meta-analysis, there was an increased attributable risk in the crude mortality in patients with infections by CRAB compared to patients with infections by CSAB (RA = 0.19 (95% CI = 0.14 to 0.24) with high heterogeneity (I2 = 66.4%, p <0.001). As sources of heterogeneity, it was investigated the length of stay, the site of infection, disease severity and use of inappropriate therapy. Among the studies that evaluated only patients with bacteremia, the risk of attributable mortality was higher (RA = 0.27; 95% CI = 0.19 to 0.34). Using meta-regression was observed a positive linear relationship between the attributable mortality risk and the standardized mean difference of APACHE II score. For investigating the presence of bias and confounding risk was evaluated descriptively the main methodological aspects necessary to observational studies evaluating the risk factors associated with attributable mortality in patients with infections caused by carbapenem-resistant A. baumannii. It was observed in this review that these studies are subject to pitfalls, including the inappropriate mode for adjustment for confounding factors of important variables (eg.: control group selection, previous exposure to antimicrobials, measurement of time in risk and gravity); besides the great heterogeneity between studies due the drawings, units of analysis and approaches to the extent of exposure and outcome, making it difficult comparison and summarization of information. Conclusions: The data of this systematic review provide evidence that attributable mortality related to the presence of infection by CRAB is higher than in patients with infection by CSAB. However, the investigation of attributable mortality has many limitations and is not conclusive yet because of the design adequacy of the study to their goals, definitions of exposure and outcome measures, metrics used in measuring results, control group selection and confounding factors. The awareness of all these elements is vital in analyzing the crude and attributable mortality.

Submitted by Erika Demachki (erikademachki@gmail.com) on 2014-10-20T17:09:26Z No. of bitstreams: 2 Dissertação - Cássia Silva de Miranda Godoy - 2012.pdf: 2252636 bytes, checksum: cdb569738a5d271a5bc6ac26e7d4dc4e (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Approved for entry into archive by Jaqueline Silva (jtas29@gmail.com) on 2014-10-20T17:39:39Z (GMT) No. of bitstreams: 2 Dissertação - Cássia Silva de Miranda Godoy - 2012.pdf: 2252636 bytes, checksum: cdb569738a5d271a5bc6ac26e7d4dc4e (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Made available in DSpace on 2014-10-20T17:39:39Z (GMT). No. of bitstreams: 2 Dissertação - Cássia Silva de Miranda Godoy - 2012.pdf: 2252636 bytes, checksum: cdb569738a5d271a5bc6ac26e7d4dc4e (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Previous issue date: 2012-03-23 / Fundação de Amparo à Pesquisa do Estado de Goiás - FAPEG / Acinetobacter baumannii (Ab), has an important role in healthcare-associated infections, present a rapid global and emerging multidrug-resistant (MDR) strains, affecting many countries. In Brazil, Ab is responsible for outbreaks infections in intensive care units (ICUs) since 1996, with high rates of antimicrobial resistance. This was a descriptive cohort study of adult infected with Ab during the period of June to December of 2010, that evaluated the clinical and epidemiological profile of infections caused by Ab and analyzed genetically, by pulsed field gel electrophoresis (PFGE), clinical isolates from patients admitted in five ICUs of the Municipality of Goiania. We identified 64 cases of patient infected or colonized with Ab during the study period, 84 samples culture positive for Ab with a global infection rate of 4.8%. Infection incidence at each hospital was as follows: 10 % in ICU-1, 4.3% in ICU-2, 7.8% in ICU-3, 1.3% in ICU-4, and 7.5 % in ICU-5. The mean age of patients was 53.2 years (sd=19) and 59.4% (38) were male. Symptomatic infections occurred in 90.6% of the cases. The most frequent site of infection was pulmonary (53.1%), followed by surgical site (10.9%), and urinary tract (7.8%). The most common underlying diseases were neoplasia (34.4%) and AIDS (17.2%). Most of the patients infected with Ab (98.4%) had received antimicrobial therapy previously. The most frequently used drugs were cephalosporins (71.4%), carbapenems (50.8%), glycopeptides (46.0%), and fluoroquinolones (33.3%). Among the invasive procedures realized prior to Ab infection, intravascular catheters and vesical catheters where the most frequent (93.7%). The culture results from the isolate of each patient revealed that carbapenems resistance was 73.4%, ampicillin-sulbactam 60.9%, amikacin 20.3%, polymyxins 6.2%, tigecycline 3.1%. The overall mortality rate was 79.7% and related mortality rate to Ab infection was 67.2%. PFGE analysis of the isolates from 56 patients demonstrated the dissemination of genetically related clones within the ICU and between the different ICUs, and the identification of a major outbreak of MDR Ab in four out of the five analyzed ICUs involving 12 patients. In conclusion a high rate of antimicrobial resistance was detected as well as a high mortality rate among ICU patients infected with Ab, requiring stronger and more efficient measures to control this agent, as well as urgent measures are needed for the rational utilization of antibiotics in ICUs. / O Acinetobacter baumannii (Ab) tem importante papel nas infecções relacionadas à assistência à saúde e apresenta emergência rápida e global de cepas multidrogarresistentes (MDR), atingindo vários países. No Brasil, o Ab é responsável por surtos de infecções em unidades de terapia intensiva (UTIs) desde 1996, com elevadas taxas de resistência aos antimicrobianos. Esse estudo foi delineado como uma coorte descritiva de pacientes adultos infectados por Ab no período de junho a dezembro de 2010. Avaliou o perfil clínico e epidemiológico das infecções causadas por Ab e analisou geneticamente, por eletroforese em gel de campo pulsado (PFGE), os isolados clínicos destes pacientes em cinco UTIs de Goiânia e Aparecida de Goiânia. Foram identificados 64 casos de pacientes infectados ou colonizados por Ab no período do estudo, 84 amostras de cultura positivas para Ab e taxa global de infecção de 4,8 %. A frequência de infecções por UTIs foi de: 10% na UTI-1; 4,3% na UTI-2; 7,8% na UTI-3 e 1,3% na UTI-4 e 7,5% na UTI-5. A média de idade dos pacientes foi de 53,2 anos (dp=19) sendo 59,4% (38) do sexo masculino. Infecção sintomática ocorreu em 90,6% dos casos. O sítio de infecção mais frequente foi o pulmonar com 53,1%, seguido de infecção do sítio cirúrgico 10,9% e trato urinário 7,8%. As doenças de base mais comuns foram neoplasia (34,4%) e AIDS (17,2%). Dos pacientes com infecção pelo Ab, 98,4% receberam antibacteriano prévio. Os antibacterianos mais usados foram: cefalosporinas 71,4% (45); carbapenêmicos 50,8% (32), glicopeptídeos 46,0% (29) e fluorquinolonas 33,3% (21). Dos procedimentos invasivos realizados previamente à infecção pelo Ab, cateter vascular central e sondagem vesical de demora (93,7%) foram os mais comuns. A letalidade global foi de 79,7% (51/64), e a relacionada às infecções pelo Ab foi de 67,2% (39/58). Avaliando os resultados de cultura positiva, a resistência aos carbapenêmicos foi de 73,4%, à ampicilina/sulbactam de 60,9% (39/64), amicacina de 20,3% (13/64), polimixinas de 6,2% (4/64) e tigeciclina de 3,1% (2/64). A análise por PFGE das isolados bacterianos dos pacientes (56), demonstrou a disseminação clonal de Ab dentro das UTIs, e entre as diferentes UTIs, com identificação de um surto por Ab MDR entre quatro das cinco UTIs investigadas no período do estudo, envolvendo 12 pacientes. Constatamos alto índice de Ab MDR e alta letalidade nas UTIs avaliadas, com necessidade de intensificar o controle deste agente, além de racionalização do uso de antimicrobianos nas UTIs.

Acinetobacter baumannii é um patógeno oportunista, geralmente resistente a muitos antimicrobianos, que causa surtos de infecções hospitalares. Assim, a sua habilidade de formar biofilme pode explicar a capacidade de sobreviver no ambiente hospitalar e em utensílios médicos. O objetivo desse estudo foi avaliar a capacidade de duas cepas clínicas de A. baumannii obtido de hospitais de Porto Alegre, Brasil (abC e abH) e uma cepa controle ATCC 19606 (abA) formar biofilme e realizar a análise transcricional dos genes possivelmente envolvidos na produção e manutenção do biofilme: bap, abaI, ompA, bfmRS, csuAB, pgaA, pilZ, wspR, eal, eagg, IscRSU e csdA. A capacidade de formação de biofilme foi avaliada pelo método cristal violeta em superfície plástica a 25°C e 37°C nos meios LB, LB + 1% glicose, urina pura e LB + 10% sangue de carneiro. A análise transcricional foi feita por real time PCR. A cepas AbH, AbC e AbA foram fortes formadoras de biofileme em LB e LB+glicose à 25 e 37°C. Em LB+sangue, as cepas AbH e AbA foram fortes formadoras e AbC foi fraca formadora de biofilme. Em urina, a cepa AbH foi moderadamente formadora, AbC e AbA foram fracas formadoras de biofilme. Os genes wspR, pgaA, ompA, bap, abaI de AbA, csdA de AbH e o operon IscRSU foram superexpressos em biofilme; os genes eagg de AbH, pilZ e csuAB foram inibidos e os genes bfmRS, eal, eagg de AbA, csdA de AbA e abaI de AbH não possuíram uma variação significativa na expressão durante o biofilme. Portantanto, a regulação positiva dos genes wspR, pgaA, ompA, bap, csdA e do operon IscRSU é um indício de sua importância na formação e manutenção do biofilme por esse patógeno. / Acinetobacter baumannii is an opportunistic pathogen which causes a wide range of nosocomial infections, being usually multirresistent to drugs. Their ability to form biofilm can explain the feature of surviving inside hospital environment and on medical devices. The aim of the present study was to evaluate the ability of two clinically isolated MDR A. baumannii strain, obtained from a general hospital of Porto Alegre, RS, Brazil (AbH and AbC), and the reference ATCC 19606 strain (AbA), to form biofilm and to analyze the relative expression of genes putatively involved in biofilm formation: bap, abaI, ompA, bfmRS, csuAB, pgaA, pilZ, wspR, eal, eagg, IscRSU e csdA. The biofilm formation capability was evaluated by the crystal-violet staining method on plastic surfaces at 25°C and 37°C using the broth LB, LB + 1% glucose, pure urine and LB + 10% sheep blood. The trancritional profiling of the genes was analyzed through real time PCR methodologies. The strains AbH, AbC e AbA were strong biofilm producers in LB e LB+glucose at 25 and 37°C. In the broth LB+blood, the strains AbH and AbA were strong biofilm producers and AbC was week biofilm producer. In urine, the strain AbH was moderated producer, AbC and AbA were week biofilm producers. The genes wspR, pgaA, ompA, bap, abaI from AbA, csdA from AbH and the operon IscRSU were overexpressed in biofilm; the genes eagg de AbH, pilZ e csuAB were suppressed and the genes bfmRS, eal, eagg from AbA, csdA from AbA e abaI from AbH did not vary their expression significantly during the biofilm condition. In conclusion, the factors wspR, pgaA, ompA, bap, csdA and of the operon IscRSU, that were positively regulated, appear to have an important role during the process of biofilm formation by A. baumannii.

A.baumannii é um importante patógeno em infecções nosocomiais principalmente por sua capacidade de se tornar resistente aos antimicrobianos. Surtos de A.baumannii resistente aos carbapenêmicos (ABRC) têm sido descritos em todo mundo. Devido à emergência de resistência aos antimicrobianos e ausência de novas opções de tratamento, as polimixinas reemergiram como opção de terapia contra infecções causadas por A.baumannii. O uso de polimixina é associado a maior mortalidade e menor eficácia comparada a outros antimicrobianos. Alguns estudos in vitro têm avaliado a combinação de polimixina com outros antimicrobianos a fim de aumentar a eficácia dos tratamentos. O objetivo deste estudo foi avaliar o sinergismo entre a polimixina B com outros antimicrobianos em isolados de ABRC, pelo método de Curvas Tempo-Morte bacteriana (Time- Kill Curves). Os isolados foram provenientes de banco de amostras e foram avaliadas as combinações de polimixina B com carbapenêmicos (imipenem e meropenem), tigeciclina, rifampicina, amicacina e ceftazidima. As combinações foram testadas nos tempo 0, 30’, 1,4,12 e 24 h. Sinergismo entre polimixina B foi demonstrado contra todos antimicrobianos para ambos isolados, exceto para ceftazidima e imipenem no isolado 1. Nosso estudo mostrou que tigeciclina, amicacina e rifampicina são agentes mais ativos combinados com polimixina B, sendo assim estes agentes podem apresentar efeito benéfico em combinação com a polimixina no tratamento de ABRC. / A.baumannii is an important pathogen in nosocomial infections primarily for its ability to become resistant to antimicrobials. Outbreaks carbapenem- resistant A.baumannii (CRAB) has been described worldwide. Due to the emergence of antimicrobial resistance and the absence of new treatment options, the polymyxins reemerged as an option therapy against infections caused by A.baumannii. The use of polymyxin is associated with higher mortality and lower effectiveness compared to other antimicrobials. In vitro studies have evaluated the combination of polymyxin with other antimicrobial agents to enhance the effectiveness of the treatments. This study was to evaluate the synergy between polymyxin B with other antimicrobials in isolates from ABRC, by Time-Kill Curves. The isolates were from stool samples and were evaluated combinations of polymyxin B with carbapenems (imipenem and meropenem), tigecycline, rifampin, amikacin and ceftazidime. The combinations were tested at time 0, 30 ', 1,4,12 and 24 h. Synergism between polymyxin B was demonstrated against all antimicrobials for both isolates, except for ceftazidime and imipenem in isolated 2. Our study showed that tigecycline, amikacin and rifampicin more active agents are combined with polymyxin B, and thus these agents may have a beneficial effect in combination with a polymyxin in treating CRAB.

Um estudo de coorte prospectivo foi realizado com o objetivo de comparar a eficácia da polimixina B à de outros antibióticos. Foram estudados pacientes com pneumonia ou traqueobronquite associadas à ventilação mecânica causadas por Pseudomonas aeruginosa ou Acinetobacter baumannii. Critérios de inclusão para este estudo foram idade igual ou superior a dezoito anos e uso de terapia antimicrobiana apropriada por período igual ou superior a 48 horas. O desfecho primário avaliado foi mortalidade em 30 dias. Variáveis clínicas foram comparadas entre os pacientes que utilizaram polimixina B e os que utilizaram outras drogas. O modelo de regressão de Cox foi realizado. Um total de 67 episódios ocorridos em 63 pacientes foi analisado: 45(67,2%) foram tratados com polimixina B e 22 (32,8%) com comparadores. A maior parte dos comparadores (72,7%) era de beta-lactâmicos. A maioria dos episódios foi de pneumonia associada à ventilação mecânica (PAV). As infecções foram causadas por P. aeruginosa em 28 casos (41,8%), por A. baumannii em 35 casos (52,2%) e por ambos em 4 casos (6%). A mortalidade geral em 30 dias foi de 44,8% (30 de 67): 53,3% (24 de 45) no grupo da polimixina B e 27,3% (6 de 22) no grupo dos comparadores (p=0,08). A taxa de mortalidade no grupo da polimixina e comparadores foi de 65,6 e 12,0 por 1000 pacientes-dia, respectivamente (p=0,02). A análise multivariada mostrou que o uso de polimixina B foi fator independente associado à mortalidade em 30 dias (Hazard Ratio ajustada, 4,3; Intervalo de Confiança de 95%, 1,39-13,03), após ajuste para tempo de internação hospitalar antes da infecção e aumento > 100% da creatinina em relação ao valor basal durante o tratamento. O escore APACHE II no inicio da infecção foi mantido no modelo final, embora não tenha atingido significância estatística, para ajuste de possível fator confundidor residual. Não houve diferenças significativas nos desfechos secundários, incluindo tempo de ventilação mecânica após terapia adequada, superinfecção e erradicação bacteriana nas secreções respiratórias. A terapia com polimixina B foi inferior comparada a outras drogas na pneumonia e traqueobronquite associadas à ventilação mecânica causadas por P. aeruginosa e A. baumannii. / To compare the efficacy of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia (VAP) and tracheobronchitis (VAT) by Pseudomonas aeruginosa or Acinetobacter baumannii, a prospective cohort study was performed. Patients who received appropriate therapy for ≥48h were analyzed. The primary outcome was 30-day mortality. A total of 67 episodes were analyzed: 45 (67.2%) treated with polymyxin B and 22 (32.8%) with comparators. Thirty-day mortality was 44.8%: 53.3% (24 of 45) in the polymyxin B group and 27.3% (6 of 22) in the comparator group, P=0.08. The mortality rates in the polymyxin B and comparator group were 65.6 and 12.0 per 1000-patients-day, respectively (P=0.02) Treatment with polymyxin B was independently associated with 30-day mortality in multivariate model, with similar results in the subgroup of patients with VAP, suggesting that this antibiotic may be inferior to other drugs in the treatment of VAP and VAT by these organisms.

鮑曼不動桿菌(Acinetobacter baumannii)是一種威脅生命的醫院獲得性病菌。該細菌有很强的環境適應能力。它能夠在重症監護室被分離出來并有很高的幾率感染免疫系統受損的病人。鮑曼不動桿菌有很高的傾向獲得多重抗藥性。目前在亞洲和歐洲有多株泛抗藥性菌株被發現。一些基因組比對研究著重報告了鮑曼不動桿菌的抗藥基因片段和與抗藥性相關的基因突變。然而，抗藥基因的轉錄調控和該細菌在抗生素治療過程中引發的反應并未得到很好的研究。因此，我們運用鏈特異性轉錄組測序技術（RNA-seq）對一些抗藥菌株和非抗藥菌株在不同環境下生長的樣本進行測序，來研究該細菌，尤其是在抗生素治療中抗藥菌株的基因轉錄調控。 / 本研究運用轉錄組測序技術（RNA-seq）系統分析了十二株鮑曼不動桿菌在培養液生長狀況下的轉錄組。本次研究共收集了九株多重抗藥性菌株和三株敏感菌株，其中包括了一些快速生長的菌株和慢速生長的菌株。在快速生長的菌株中，氨基酸代謝途徑、甘油脂代謝途徑和钳铁化合物生物合成途徑被向上調控並扮演着重要角色。多重抗藥性菌株擁有更多與轉位酶（transposase）相關的抗生素抗性基因，但除此之外，在對數期的生長過程中多重抗藥性菌株與敏感菌株並未在許多其他代謝途徑中表現差異性控制。 / 三株擁有相同脉冲场凝胶电泳（PFGE）樣式但是表現出不同抗藥性的菌株分別生長於含有阿米卡星(Amikacin)、亞胺培南（Imipenem）或美羅培南（Meropenem）的培養液中，然後它們的轉錄組也被進行了研究。菌株生長在含有抗生素的培養液中時，與能量製造相關的的途徑和核醣體合成途徑被向上調控。作用機制不同的抗生素對細菌有不同的影響，阿米卡星誘發更多基因被向上調控，例如與蛋白質折疊相關的基因；碳青霉烯类抗生素誘發更多的基因被向下調控，例如甘油脂代謝途徑。然而，許多在抗生素治療過程中被緊密調控的基因功能仍舊未知。在抗生素環境生長的條件下基因調控和抗藥機制可能會更複雜。 / 最後，本研究找到一些新的與抗藥性相關的基因和单核苷酸变异（SNVs）。其中，源自於同一操縱子的大环内酯二位轉磷酸酶（macrolide2’ phosphotransferase）同源體Mph和大环内酯外排泵蛋白同源體Mel只存在並一同表達於鮑曼不動桿菌的阿米卡星抗藥株中。這兩個基因或對阿米卡星的抗藥性有一定貢獻作用。總而言之，這些成果爲將來的深度研究提供了重要依據。 / Acinetobacter baumannii is a life-threatening nosocomial pathogen, which has versatile adaptability to the environment. It can be isolated from intensive care unit (ICU) and causes high prevalence of infection among immunocompromised patients. A. baumannii has high tendency to develop multidrug resistance. Currently, pan-drug resistant strains have been reported in Asia and Europe. Several comparative genomic studies revealed the structures of drug resistant islands and antibiotic-related mutations in A. baumannii. However, the transcriptional regulation of drug resistant genes, and the multidrug resistant response of A. baumannii under the treatment of antibiotics are not well studied. By applying strand-specific RNA-sequencing on sensitive and multidrug resistant strains growing in various conditions, we aimed to study the transcriptional responses and gene regulation of A. baumannii, specifically under the antibiotic treatment. / The transcriptome of twelve A. baumannii strains, including nine multidrug resistant strains and three sensitive strains, were systematically analyzed in planktonic state by RNA-seq. Among the multidrug resistant strains there are both fast-and slow-growing strains. Amino acid metabolic pathways, glycerol lipid metabolic pathways and siderophore biosynthetic process are found to be key pathways that are up-regulated in fast-growing strains. Except that multidrug resistant strains possess more transposase-associated antibiotic resistant genes, intriguingly, only a few pathways are differentially regulated between multidrug resistant and sensitive strains during fast growth in antibiotic-free medium. / Three strains of the same PFGE pattern but with different antibiotic resistance patterns were treated by amikacin, imipenem, and meropenem, and their transcriptomes were analyzed. The energy generation-related pathways and ribosome synthesis pathway were commonly up-regulated when the strains were grown in antibiotic-treated media. Amikacin triggers more genes up-regulated, including genes responsible for protein folding, while carbapenems trigger more genes down-regulated, including glycerol lipid metabolic process, revealing the different actions of antibiotics. However, many tightly-regulated genes during antibiotic treatment were functionally unknown, suggesting that gene regulation during antibiotic response and the actual mechanisms involved could be far more complex. / Finally, this study also identified several novel genes and single nucleotide variations (SNVs) which were correlatedto antibiotic-specific resistance. A macrolide 2’ phosphotransferase homolog Mph and a macrolide efflux protein homolog Mel, which commonly exist only in A. baumannii amikacin resistant strains and are co-expressed in the same operon, may contribute to amikacin resistance. In summary, the results presented in this thesis have opened the venue for future investigations. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Qin, Hao. / Thesis (Ph.D.) Chinese University of Hong Kong, 2014. / Includes bibliographical references (leaves 107-114). / Abstracts also in Chinese.